ADD/ADHD has been a provocative topic in lay and professional communities for decades: What is it? Does it really exist? What causes it? How is it diagnosed? Is it over-diagnosed? Is it really a significant health issue? Why are so many people being diagnosed with it?
A key driver behind many of these questions is the fact that effective treatment of ADD/ADHD more often than not necessitates the use of controlled substances to treat a problem that just does not seem that serious to many individuals.
The front-line medications for ADD/ADHD, the methylphenidate and amphetamine based stimulants, provoke strong feelings, namely, worry and fear in most patients and, unfortunately, in many professionals involved in their care.
Because of these fears, some well founded and some not, many patients with legitimate concerns go undiagnosed while others do not get treated or are treated with sub-therapeutic dosage regimens. As a result, their short and long term outcomes are not optimal and the chances of developing significant secondary co-morbidities increase.
Over the past 35 years, in our ADD/ADHD specialty practice in Pittsburgh and at various satellite locations, we have diagnosed and successfully treated more than 10,000 patients (greater then a 90% success rate).
We have accomplished this high degree of success by rigidly adhering to a comprehensive, multidisciplinary approach that is individualized to the needs of each patient. We have created systematic evidence-based protocols which we have refined by consistently applying them to our patients and continuously assessing their efficacy and cost effectiveness/efficiency.
We have developed a particular expertise in the use of medication in the treatment of ADD/ADHD. To achieve a high degree of success when it comes to medication treatment for ADD/ADHD we have found that it is commonly necessary for us to use off-label medication doses and regimens (i.e., for any medication dosage form, dosage regimen, population, or other use presently not mentioned in the FDA approved manufacturers’ marketing guidelines).
Predictably this differentiated use can magnify the inherent fear many patients, family members, uninformed physicians, and pharmacists have about the stimulant medications and can put us at odds with insurance companies that are increasingly restricting their formularies for ADD/ ADHD medications by imposing arbitrary quantity limits for these medications and failing to reimburse off-label uses of stimulant medications to treat ADD/ADHD.
Our sense is that appropriate treatment of ADD/ADHD with proper dosing of medication is going to emerge as a significant health care issue.
We are eager to work with others to resolve this important health care problem. We are confident that if we work together we can come up with a more appropriate set of guidelines for the use of stimulant medications in the treatment of ADD/ADHD so that these individuals can receive a higher quality of medical care and better long-term outcomes.
We believe that cost effective and efficient management of a common problem like ADD/ADHD, such as we provide with our approach, can be a cornerstone to reducing overall health care costs.
Find more honest answers and resources you can trust at TRANShealth Inc, a non-profit organization that imagines a future where accurate diagnosis and effective treatment for ADD is the norm. TRANShealth seeks to educate, inform, guide, and cheerlead individuals pursuing a path to overcome the challenges of ADD/ADHD.